Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Carcinoma, Renal Cell 2

Interventions

pembrolizumab 184Magnetic Resonance Spectroscopy 162Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 93Radiosurgery 91Prednisone 81Androgen Antagonists 80Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 63Ipilimumab 61Biopsy 61abiraterone 58cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 51Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37olaparib 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
vorolanib × Genitourinary × 1 year × Clear all
NCT07386158 2026-02-04

Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

Sun Yat-sen University

Phase 2 Recruiting
21 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07047001 2025-07-09

Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Active not recruiting
60 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡